A Safety, Tolerability and Efficacy Study With QBW251 in COPD Patients With QBW251
Public ClinicalTrials.gov record NCT02449018. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double Blind, Placebo Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Multiple Doses of QBW251 in Patients With COPD
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
To evaluate the efficacy, safety and tolerability of multiple doses of QBW251 vs placebo administered orally, on airway function, lung volume, and quality of life in patients with chronic obstructive pulmonary disease (COPD)
Study identification
- NCT ID
- NCT02449018
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 92 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 30, 2015 (Actual)
- Primary completion
- Dec 27, 2016 (Actual)
- Completion
- Jan 23, 2017 (Actual)
- Last update posted
- Jan 5, 2021
2015 – 2017
United States locations
- U.S. sites
- 14
- U.S. states
- 9
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Novartis Investigative Site | Birmingham | Alabama | 35294 | — |
| Novartis Investigative Site | Fullerton | California | 92835 | — |
| Novartis Investigative Site | Waterbury | Connecticut | 06708 | — |
| Novartis Investigative Site | Clearwater | Florida | 33765 | — |
| Novartis Investigative Site | Port Orange | Florida | 32127 | — |
| Novartis Investigative Site | Tampa | Florida | 33603 | — |
| Novartis Investigative Site | Normal | Illinois | 61761 | — |
| Novartis Investigative Site | St Louis | Missouri | 63141 | — |
| Novartis Investigative Site | Huntersville | North Carolina | 28078 | — |
| Novartis Investigative Site | Shelby | North Carolina | 28152 | — |
| Novartis Investigative Site | Medford | Oregon | 97504 | — |
| Novartis Investigative Site | Simpsonville | South Carolina | 29681 | — |
| Novartis Investigative Site | Spartanburg | South Carolina | 29303 | — |
| Novartis Investigative Site | Union | South Carolina | 29379 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02449018, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 5, 2021 · Synced Oct 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02449018 live on ClinicalTrials.gov.